Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.

British journal of cancer - 1 Nov 2021

Chatzipli Aikaterini, Bonnefoi Hervé, MacGrogan Gaetan, Sentis Julie, Cameron David, Poncet Coralie, Iggo Richard

Abstract excerpt

BACKGROUND: Treatment of patients with residual disease after neoadjuvant chemotherapy for breast cancer is an unmet clinical need. We hypothesised that tumour subclones showing expansion in residual disease after chemotherapy would contain mutations conferring drug resistance. METHODS: We studied oestrogen receptor and/or progesterone receptor-positive, HER2-negative tumours from 42 patients in the EORTC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Gene Regulatory Networks

Share to Neoadjuvant Therapy

Share to Neoplasm, Residual

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 34480095
DOI: 10.1038/s41416-021-01526-3
PMCID: PMC8575785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.PMID 34480095Read ↗

Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease.Semantic proximity Read ↗

Complex rearrangements fuel ER+ and HER2+ breast tumoursSemantic proximity Read ↗

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatmentsSemantic proximity Read ↗

Subclonal evolution in the mutational landscape of early Triple negative breast cancer (TNBC) on multi-agent chemotherapy: Comparison of Pre- And Post-Neoadjuvant Chemotherapy (NAC) Samples Of TNBC Patients With Residual DiseaseSemantic proximity Read ↗

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancersSemantic proximity Read ↗

Frequent Whole-Genome Duplication Events Drive the Genomic Evolution of Triple-Negative Breast Cancer During Neoadjuvant ChemotherapySemantic proximity Read ↗

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.Semantic proximity Read ↗

The clonal architecture and tumour microenvironment of breast cancers are shaped by neoadjuvant chemotherapySemantic proximity Read ↗

Concordance of genomic alterations between primary and recurrent breast cancer.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.